Cancer Insulin Potentiation Therapy Treating

Women suffering from recurrent ovarian cancer may have a new treatment regimen that may increase the response to treatment and prolong their lives. Doctors at H. Lee Moffitt Cancer Center & Research Institute are testing a combination of chemotherapy and the drug Avastin in these patients. Moffitt opened a clinical trial recently and is looking for new participants for the study.

"We can often get the cancer to shrink for periods of time, but ultimately, it becomes resistant to standard chemotherapies," said Dr. Robert Wenham, member of the gynecologic oncology program at Moffitt. "The hope is that by using these targeted therapies, we can prolong and manage the cancer making it more of a chronic disease process rather than something that's going to take the patient's life."

The clinical trial will address ovarian cancers that are incurable and tough to treat.

Unlocking cancer's secrets

PREDICT is the B.C. Cancer Agency's new research project at its Vancouver Island centre. An acronym for Personalized Response Determinants in Cancer Therapy, the program could just as easily have been tagged SMART -- simple, measurable, achievable, realistic and timely.

.

Anti-Cancer Activity Supports Further Development of Ispinesib in ...

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 06/28/07 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the final results from a multicenter Phase II clinical trial sponsored by GlaxoSmithKline (GSK), which evaluated ispinesib in patients with locally advanced or metastatic breast cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases.

This Phase II clinical trial was designed to evaluate the safety and efficacy of ispinesib in the second- or third-line treatment of patients with locally advanced or metastatic breast cancer whose disease had recurred or progressed despite treatment with anthracyclines and taxanes.